Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 46

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 46
---
B) 33.333 and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per-share exercise price for Common Stock issuable upon exercise of each Continuing Officer Option was correspondingly adjusted by dividing (A) the per-share exercise price of the Series A Preferred Stock subject to such Continuing Officer Option, by (B) 33.333 and rounding the resulting exercise price up to the nearest whole cent.

As a result of the Merger, Drs. Kurtoglu and Jewell were granted Continuing Officer Options as summarized below:

| Named Executive Officer     |     | Number of Securities Underlying Unexercised Options Exercisable(1) |     | Number of Securities Underlying Unexercised Options Not Yet Exercisable(1) |     | Option Exercise Price |     | Option Expiration Date |
| Metin Kurtoglu, M.D., Ph.D. |     |                                                            213,820 |     |                                                                          — |     |                 $1.41 |     | 11/6/2026              |
| 14,254                      |     |                                                                  — |     |                                                                      $3.23 |     |             4/25/2031 |     |                        |
| 3,563                       |     |                                                             10,691 |     |                                                                      $3.23 |     |             2/29/2032 |     |                        |
| Christopher Jewell, Ph.D.   |     |                                                             84,638 |     |                                                                     57,909 |     |                 $3.23 |     | 1/15/2033              |

(1) The Continuing Officer Options were exercisable initially only for shares of Series A Preferred Stock. Following the conversion of the majority of the Company’s outstanding shares of Series A Preferred Stock, the Continuing Officer Options were converted into options to purchase shares of Common Stock. The numbers of shares presented in this column are shares of Common Stock.

#### Retention Bonuses
On August 25, 2023, our Board approved a one-time cash bonus payment (each, a “Retention Bonus” and together, the “Retention Bonuses”) to certain of our then-current executive officers equal to a multiplier of that executive officer’s annual base salary for 2023, including Dr. Brunn (2x annual base salary) and Mr. Davis (2x annual base salary), provided that each such Retention Bonus recipient remains employed by us in good standing on March 31